Not So Different: How Henlius is Making Its Mark on the Global Biosimilar Industry

June 20, 2021

Ping Cao, vice president of Business Development for Shanghai Henlius Biotech, discussed the company's current biosimilar development plans and the process for getting regulatory approval for biosimilars in China.

Opinion: Biosimilars Can Aid in Post–COVID-19 Health Care Financial Recovery
News Roundup: Amneal's Bevacizumab Biosimilar, Originator Pricing Impact, and More
Alvotech Achieves Milestone in Bid to Capture Adalimumab Share
The Top 5 Biosimilar Articles for the Week of June 14